Find Belumosudil manufacturers, exporters & distributors on PharmaCompass

Belumosudil Mesylate

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 1 USDMF, 2 NDC API, 2 Listed Suppliers, $ API Reference Price

3 API Suppliers
1 USDMF
2 NDC API
2 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

1 FDF Dossiers
1 FDA Orange Book

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 10 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
10 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Annual Reports

globalSalesInformation
1 US Medicaid Prescriptions
2 Annual Reports

MARKET PLACE

1 APIs

marketPlace
1 APIs

PATENTS & EXCLUSIVITIES

5 US Patents, 2 US Exclusivities

patents
5 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

100,434,804

Annual Reports (USD Million)

562

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 911417-87-3, Slx-2119, Belumosudil, Kd-025, Kd025, Rock inhibitor 2

Molecular Formula

C₂₆H₂₄N₆O₂

Molecular Weight

452.5 g/mol

InChI Key

GKHIVNAUVKXIIY-UHFFFAOYSA-N

FDA UNII

834YJF89WO

Belumosudil is an orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.

1 2D Structure

Belumosudil

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide

2.1.2 InChI

InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)

2.1.3 InChI Key

GKHIVNAUVKXIIY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5

2.2 Other Identifiers

2.2.1 UNII

834YJF89WO

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Belumosudil

2. Rezurock

2.3.2 Depositor-Supplied Synonyms

1. 911417-87-3

2. Slx-2119

3. Belumosudil

4. Kd-025

5. Kd025

6. Rock Inhibitor 2

7. Rezurock

8. Belumosudil [usan]

9. Slx 2119

10. Slx-2119 Free Base

11. Rock2 Inhibitor Kd025

12. 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide

13. Slx2119

14. 834yjf89wo

15. C26h24n6o2

16. Kd025 (slx-2119)

17. Acetamide, 2-(3-(4-(1h-indazol-5-ylamino)-2-quinazolinyl)phenoxy)-n-(1-methylethyl)-

18. 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-n-isopropylacetamide

19. 2-[3-[4-(1~{h}-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-~{n}-propan-2-yl-ethanamide

20. 2-[3-[4-(1h-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-n-(1-methylethyl)-acetamide

21. 2-[3-[4-[(1h-indazol-5-yl)amino]quinazolin-2-yl]phenoxy]-n-isopropylacetamide

22. Unii-834yjf89wo

23. Kinome_2597

24. Belumosudil [inn]

25. Belumosudil [who-dd]

26. Schembl878202

27. Gtpl9558

28. Chembl2005186

29. Dtxsid80238425

30. Bdbm322155

31. Bdbm435505

32. Bcp15921

33. Ex-a2314

34. Kd 025

35. Mfcd23098791

36. S7936

37. Who 11343

38. Zinc63298464

39. Slx-2119(kd-025)

40. Slx-2119; Kd-025

41. Us10570123, Example 232

42. Ccg-269256

43. Cs-0776

44. Sb16915

45. Ncgc00378903-01

46. Ncgc00378903-02

47. Ac-33057

48. As-35230

49. Hy-15307

50. Db-103511

51. Us10183931, Slx-2119

52. A855956

53. Q27269397

54. 2-(3-{4-[(1h-indazol-5-yl)amino]quinazolin-2-yl}phenoxy)-n-(propan-2-yl)acetamide

55. 2-[3-[4-(1h-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-n-(1-methylethyl)acetamide

56. Icq

2.4 Create Date

2006-11-20

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₄N₆O₂
Molecular Weight	452.5 g/mol
XLogP3	4.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	7
Exact Mass	452.19607403 g/mol
Monoisotopic Mass	452.19607403 g/mol
Topological Polar Surface Area	105 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	678
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Belumosudil is indicated for the treatment of chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years of age and older following failure of at least two other lines of systemic therapy.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Belumosudil appears to inhibit several pro-fibrotic and pro-inflammatory processes in order to prevent and treat the damage incurred by graft-versus-host disease. Given its mechanism of action and findings in animal trials, belumosudil is considered to carry embryo-fetal toxicity and may cause significant harm to a developing fetus should a pregnant mother be exposed. Female patients of reproductive potential, or male patients with female partners of reproductive potential, should be advised to use effective contraception during treatment with belumosudil and for one week after the last dose.

5.2 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

5.3 ATC Code

L - Antineoplastic and immunomodulating agents

L04 - Immunosuppressants

L04A - Immunosuppressants

L04AA - Selective immunosuppressants

L04AA48 - Belumosudil

5.4 Absorption, Distribution and Excretion

Absorption

Following oral administration, the mean bioavailability of belumosudil is 64% and the median T_max at steady-state is 1.26 to 2.53 hours. As compared to administration in a fasted state, belumosudil C_max and AUC increased by 2.2 and 2 times, respectively, when administered with a high-fat, high-calorie meal.

Route of Elimination

Belumosudil is eliminated primarily in the feces. Following the administration of a radiolabeled oral dose of belumosudil in healthy subjects, approximately 85% of the radioactivity was recovered in the feces, 30% of which was unchanged parent drug, with less than 5% recovered in the urine.

Volume of Distribution

Following a single oral dose of belumosudil in healthy subjects, the mean geometric volume of distribution was 184 L.

Clearance

The mean clearance of belumosudil is 9.83 L/h.

5.5 Metabolism/Metabolites

The _in vitro_ metabolism of belumosudil occurs primarily via CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, and UGT1A9. The specific metabolites generated by belumosudil metabolism remain unclear.

5.6 Biological Half-Life

The mean elimination half-life of belumosudil following oral administration is 19 hours.

5.7 Mechanism of Action

Chronic graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation in which the transplanted donor T-cells recognize the recipient's tissues as foreign and mount an immune response. During the conditioning regimen prior to stem cell transplantation (e.g. involving irradiation or chemotherapy) the host tissues can become damaged which results in downstream inflammatory responses and the generation of inflammatory mediators like TNF-alpha and IL-1. These cytokines increase the expression of host major histocompatibility (MHC) antigens and adhesion molecules which enhances the ability of mature donor T-cells to recognize these molecules. The activation of these donor T-cells results in the activation of mononuclear phagocytes, whose effector functions are triggered by stimulatory molecules generated by the damage incurred during the conditioning phase of treatment. Activated macrophages and cytotoxic T-lymphocytes begin to directly lyse target cells and/or cause their apoptosis, which eventually leads to local tissue damage and further inflammatory responses. Belumosudil is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a protein that plays a vital role in the pathogenesis of immune and fibrotic diseases. The inhibition of ROCK2 has been shown to resolve immune dysregulation by down-regulating pro-inflammatory Th17 cells and up-regulating regulatory T-cells by manipulating the phosphorylation of STAT3 and STAT5.

API SUPPLIERS

01

HRV Global Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #6.1A32

TAPI offers customized CDMO Solutions for API development and manufacturing services.

Contact Supplier

Israel

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Corporate PDF

03

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Msn Organics Private Ltd

Country

DDL Conference

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

01

Catalent Micron Technologies, Inc.

U.S.A

DDL Conference

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

HRV Global Life Sciences

India

DDL Conference

Not Confirmed

HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Contact Supplier

India

Virtual Booth

Digital Content

Belumosudil

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.

02

TAPI Technology & API Services

Israel

CPhI WW Frankfurt

Booth #6.1A32

TAPI offers customized CDMO Solutions for API development and manufacturing services.

Contact Supplier

Israel

Virtual Booth

Digital Content

Belumosudil

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.

Corporate PDF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

Belumosudil Mesylate (50 g - 100 g) API needed in India [ENA21246]

A CRO that provides formulation and analytical development services for OSDs, parenteral and liquid orals is looking for suppliers of Belumosudil Mesylate (50 g - 100 g) API for development purposes. The suppliers must support this enquiry with USDMF (optional) & CoA.

28 Nov 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

01

KADMON PHARMS LLC

France

DDL Conference

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2035-04-09

BELUMOSUDIL MESYLATE

US Patent Number : 11311541

Drug Substance Claim :

Drug Product Claim :

Application Number : 214783

Patent Use Code : U-3369

Patent Use Description :

Patent Expiration Date : 2035-04-09

Portfolio PDF

Product Web Link

02

KADMON PHARMS LLC

France

DDL Conference

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2033-10-07

BELUMOSUDIL MESYLATE

US Patent Number : 10696660

Drug Substance Claim :

Drug Product Claim :

Application Number : 214783

Patent Use Code : U-3246

Patent Use Description :

Patent Expiration Date : 2033-10-07

Portfolio PDF

Product Web Link

03

KADMON PHARMS LLC

France

DDL Conference

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2033-10-07

BELUMOSUDIL MESYLATE

US Patent Number : 10183931

Drug Substance Claim :

Drug Product Claim :

Application Number : 214783

Patent Use Code : U-3246

Patent Use Description :

Patent Expiration Date : 2033-10-07

Portfolio PDF

Product Web Link

04

KADMON PHARMS LLC

France

DDL Conference

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2029-10-30

BELUMOSUDIL MESYLATE

US Patent Number : 8357693

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214783

Patent Use Code : U-3247

Patent Use Description :

Patent Expiration Date : 2029-10-30

Portfolio PDF

Product Web Link

05

KADMON PHARMS LLC

France

DDL Conference

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Patent Expiration Date : 2042-07-14

BELUMOSUDIL MESYLATE

US Patent Number : 12097202

Drug Substance Claim :

Drug Product Claim :

Application Number : 214783

Patent Use Code : U-4014

Patent Use Description :

Patent Expiration Date : 2042-07-14

Portfolio PDF

Product Web Link

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Post Enquiry

Market Place

Find Belumosudil manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers

1 USDMF

2 NDC API

2 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers

1 FDA Orange Book

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

10 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

2 Annual Reports

MARKET PLACE

1 APIs

PATENTS & EXCLUSIVITIES

5 US Patents

2 US Exclusivities

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 11,743

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

01

02

03

01

Msn Organics Private Ltd

01

Msn Organics Private Ltd

01

01

02

01

02

03

04

05

What are you looking for?